Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | ATF4 | P18848 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.39 |
| ▸ | POLB | P06746 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP2 | O75604 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.35 |
| ▸ | ADIPOR2 | Q86V24 | 1/20 | 0.34 |
| ▸ | ADIPOR1 | Q96A54 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24225695 | 0.77 | NPSR1 (0.46) | NPSR1ATF4MEN1KMT2ALMNA | |
| SCHEMBL13654245 | 0.77 | EPHX2 (0.44) | L3MBTL1MEN1KMT2A | |
| SCHEMBL21882064 | 0.75 | EPHX1 (0.53) | NPSR1ATF4POLBMEN1KMT2A | |
| SCHEMBL24225625 | 0.74 | MAPT (0.41) | NPSR1ATF4L3MBTL1POLBSMN1; SMN2 | |
| SCHEMBL21882071 | 0.74 | HTT (0.35) | ALDH1A1SMN1; SMN2 | |
| SCHEMBL13654294 | 0.71 | LTA4H (0.38) | POLBALDH1A1SMN1; SMN2 | |
| SCHEMBL12425051 | 0.71 | EPHX1 (0.37) | POLBALDH1A1SMN1; SMN2SIGMAR1 | |
| SCHEMBL13654292 | 0.70 | ATM (0.44) | ALDH1A1ATM | |
| SCHEMBL24352353 | 0.69 | KDM4E (0.40) | KMT2ALMNASMN1; SMN2HPGDSIGMAR1 | |
| SCHEMBL13654274 | 0.68 | POLB (0.53) | L3MBTL1POLBALDH1A1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | Praxis Biotech LLC (US) | 2021-11-09 | — | — | US | disclosed |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | Praxis Biotech LLC | 2020-04-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11166942-B2 | Inhibitors of integrated stress response pathway | ATF4, DDIT3, ATF1 | NPSR1 1399/4885ATF4 1/4885L3MBTL1 1975/4885 |
| US-20200101047-A1 | INHIBITORS OF INTEGRATED STRESS RESPONSE PATHWAY | ATF4, DDIT3, ATF1 | NPSR1 1399/4885ATF4 1/4885L3MBTL1 1975/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.